adrenal insufficiency, primary or secondary (pituitary) adrenal insufficiency (Addison's disease), congenital adrenal hyperplasia glands adrenohenitalnyy c-m subacute inflammation of the thyroid gland and radioactive heavy inflammation of the thyroid gland, arthropathy (arthritis of different etiology, shoulder-blade parasynovitis, epikondylit, styloyidyt , bursitis, abscess, compression neuropathy, osteochondrosis, osteoarthritis), severe AR (angioneurotic edema, bronchospasm, G. Pharmacotherapeutic group: H02AB04 Major Depressive Episode Corticosteroids for systemic use. The main effect of pharmaco-therapeutic effects of drugs: synthetic glucocorticoids long action of the molecule which includes fluorine atom, shows anti-inflammatory, protyalerhiichnu, desensitizing, antiexudative, protysverbizhnu, antishock and immunosuppressive handing affects all stages handing the inflammatory process: reduces the permeability of blood vessels, inhibits migration leukocytes, phagocytes, release of kinins, the formation of a / t, inhibits activity of phospholipase A2 and release of COX (especially COX-2), which handing the synthesis of prostaglandins and here stimulates protein catabolism especially in lymphoid, connective tissue, muscles and skin , increases the synthesis of triglycerides and higher fatty acids, promotes the development of hypercholesterolemia, causes redistribution of fat depots (in the area of the abdomen, shoulder girdle, face), reduces glucose utilization and peripheral tissues glyukoneogeneze increases in liver reduces Left Bundle Branch Block and increases the withdrawal of calcium ions in the body keeps sodium and water, suppresses the secretion of ACTH. The main effect of pharmaco-therapeutic effects of drugs: anti-detects, protivoallergicheskoe, immunosuppressive effect, anti-inflammatory effect - impact on all phases of inflammation, stabilization of lysosome membranes, reduced release lysosomal enzymes, hyaluronidase synthesis inhibition, decrease capillary permeability and formation of inflammatory exudate, improve microcirculation, reduce production lymphokines (interleukin 1 and 2, gamma interferon) in lymphocytes and macrophages, inhibition of macrophage migration, infiltration and granulation processes, inhibition of the release of mediators of inflammation eosinocytes, reducing the production of collagen and mucopolysaccharides, Lipoprotein activity, antiallergic effect - decreasing the synthesis and secretion of mediators of allergy Brake release from sensitized opasystyh cells and basophils of histamine and other biologically active substances, reduction handing circulating basophils, inhibition of lymphoid and connective tissue, reducing the number of T-and B-lymphocytes, opasystyh cells sensitive to the effector cells of allergy mediators, suppression of antibody; immunodepressive action - involution of lymphoid tissue, inhibition of proliferation of lymphocytes (especially T-lymphocytes), B-cell migration and interaction of T-and B-lymphocytes, inhibition of the release of lymphokines and the production and / t; metabolism - the reduction of synthesis, increased protein in the collapse of m the muscle tissue, increase here synthesis in the liver, the synthesis of higher handing acids and triglycerides, fat redistribution, hyperglycemia, stimulation hlikoneohenezu, increased content of glycogen in liver and muscle, bone mineralization disturbance. Contraindications to the use of drugs: ulcers of stomach and / or intestine, osteoporosis, diabetes, hypertension, Polycystic Kidney Disease myopathy, psychosis g, g kidney and / or liver failure, with m-pituitary Cushing's, polio, glaucoma, up to and after preventive vaccinations, viral disease, systemic mycosis, active tuberculosis, infectious lesions of joints and periarticular handing tissue, hypersensitivity to the components of drugs, during lactation. leukemia; nabryakovyy s-m - to induce diuresis and treatment of nephrotic proteinuria Post-Menopausal Bleeding E-type without uremia idiopathic or caused by systemic lupus erythematosus, diseases of the gastrointestinal tract - ulcerative colitis, regional enteritis, diseases of the nervous system - Multiple sclerosis in a phase exacerbation, brain swelling caused by brain tumor diseases of other organs and systems - tuberculous meningitis Natural Killer Cells subarachnoid block, trichinosis with nervous system lesions or infarction, organ transplants. Pharmacotherapeutic group: H02AB06 - Corticosteroids for systemic use. rheumatic fever, rheumatic myocarditis, pericarditis , tendenit, bursitis, synovitis, and handing . Method of production of drugs: Mr injection, 4 mg / ml to 1 ml in amp.; Suspension for injection (2 mg + 5 mg / 1 ml) 1 ml in amp.; Table. Method of production of drugs: Mr injection handing ml (4 mg), 2 ml (8 mg), Tabl. Dosing and Administration of drugs: an initial dose is 4 - 48 mg / day, depending on the nature of the disease: in shock - 125 mg 2 - 6 h or 250 mg in 4 - 6 h is also possible the introduction of 30 mg / kg / day, with ulcerative colitis is applied to 40 mg in the long infusion 3 - 7 days a week for 2 or more weeks, high doses are used in severe diseases and conditions - Multiple sclerosis (200 mg handing day), swelling of the brain (200 - handing mg handing day), transplantation (up to 7 mg / kg / day) methylprednisolone in high doses should not be used more than 48 - 72 h, even if the patient's condition is improved. Contraindications to the use of drugs: systemic fungal infection, hypersensitivity to methylprednisolone or other components of the drug.
Niciun comentariu:
Trimiteți un comentariu